AstraZeneca Investor Conference Presentation Deck
Key upcoming newsflow and selected next wave pipeline
12
sta
Regulatory
decision
Key Phase
III data
readouts
H1 2023
Imfinzi - biliary tract cancer (TOPAZ-1) (EU)
Imfinzi - liver cancer (1L) (HIMALAYA) (EU)
Enhertu - HER2-low breast cancer (3L)
(DESTINY-Breast04) (EU)
Enhertu - HER2+ gastric cancer (2L)
(DESTINY-Gastric01) (EU)
Enhertu - HER2+ breast cancer (2L)
(DESTINY-Breast03) (CN)
Enhertu - HER2-low breast cancer (3L)
(DESTINY-Breast04) (JP, CN)
Farxiga - HFpEF (DELIVER)
PT027-asthma (MANDALA/DENALI) (US)
Ultomiris - NMOSD (CHAMPION-NMOSD)
Tagrisso - EGFRm NSCLC (1L) (FLAURA2)
Imfinzi - SCLC (limited-stage) (ADRIATIC)
Imfinzi - NSCLC (neoadjuvant) (AEGEAN)
Imfinzi - liver cancer (adjuvant) (EMERALD-2)
Lynparza - ovarian cancer (1L) (DUO-O)
Dato-DXd - NSCLC (3L) (TROPION-Lung01)
roxadustat - anaemia of myelodysplastic syndrome
Oncology BioPharmaceuticals Rare Disease
H2 2023
Beyfortus - RSV (US)
Soliris-gMG (CN)
Koselugo - NF1-PN (SPRINT) (CN)
Tagrisso - EGFRm NSCLC
(unresectable Stg. III) (LAURA)
Imfinzi - NSCLC (unresectable, Stg. III) (PACIFIC-2)
Imfinzi- bladder cancer
(muscle invasive) (NIAGARA)
Imfinzi - bladder cancer (1L) (NILE)
Lynparza - endometrial cancer (1L) (DUO-E)
Enhertu - HER2-low breast cancer (2L)
(DESTINY-Breast06)
Calquence - MCL (1L) (ECHO)
capivasertib-TNBC (locally adv./met.)
(CAPItello-290)
Farxiga - myocardial infarction (DAPA-MI)
Fasenra - EGPA (MANDARA)
Fasenra-HES (NATRON)
Next wave early pipeline
AZD8205 - B7H4 Top1i ADC
AZD0486-CD3xCD20 TCE
AZD9592 - EGFR/CMET Top1i ADC
volrustomig - PD1/CTLA4 bispecific
AZD5851 GPC3 armoured CAR-T
AZD2693- PNPLA3
AZD3427 - relaxin
AZD0780oPCSK9
AZD6793 - IRAK4
AZD8630 - ITSLP
vemircopan - oral Factor D
gefurulimab - C5 mini-body
ALXN1850 - ng asfotase alfa
ALXN1820-anti-properdin
1L = 1st-line; 2L = 2nd-line; 3L = 3rd-line; HER2-low = human epidermal growth factor receptor 2-low; HER2+ = human epidermal growth factor receptor 2-positive; HFpEF = heart failure with preserved ejection faction; NMOSD = neuromyelitis optica spectrum disorder; EGFRm = epidermal growth factor
receptor mutated; SCLC = small cell lung cancer; NSCLC = non-small cell lung cancer; Dato-DXd = datopotamab deruxtecan; RSV = respiratory syncytial virus; gMG = generalised myasthenia gravis; NF1= neurofibromatosis type 1; PN = plexiform neurofibromas; MCL = mantle cell lymphoma; TNBC = triple
negative breast cancer; EGPA = eosinophilic granulomatosis with polyangiitis; HES = hyper eosinophilic syndrome; ADC = antibody-drug conjugate; TCE = T-cell engager; PD1 = programmed cell death protein 1; CTLA4 = cytotoxic T-lymphocyte associated protein 4; CAR-T = chimeric antigen receptor (CAR) T-
cell therapy; PNPLA3 = patatin-like phospholipase domain-containing protein 3; PCSK9 = proprotein convertase subtilisin/kexin type 9; IRAK4 = interleukin-1 receptor-associated kinase 4; iTSLP = inhaled thymic stromal lymphopoietin; ng = next-generation. Collaboration partners: Merck (Lynparza), Daiichi
Sankyo (Enhertu, Dato-DXd), Sanofi (Beyfortus), Amgen (Teszpire), Avillion (PT027).View entire presentation